IL83687A - Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions - Google Patents
Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositionsInfo
- Publication number
- IL83687A IL83687A IL8368787A IL8368787A IL83687A IL 83687 A IL83687 A IL 83687A IL 8368787 A IL8368787 A IL 8368787A IL 8368787 A IL8368787 A IL 8368787A IL 83687 A IL83687 A IL 83687A
- Authority
- IL
- Israel
- Prior art keywords
- receptor
- foreign agent
- substance
- binding
- endogenous receptor
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 title claims description 5
- 102000005962 receptors Human genes 0.000 claims abstract description 50
- 108020003175 receptors Proteins 0.000 claims abstract description 50
- 230000027455 binding Effects 0.000 claims abstract description 43
- 239000000126 substance Substances 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 15
- 102000034337 acetylcholine receptors Human genes 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 108010009685 Cholinergic Receptors Proteins 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 3
- 239000002581 neurotoxin Substances 0.000 claims abstract 4
- 231100000618 neurotoxin Toxicity 0.000 claims abstract 4
- 230000002156 curarimimetic effect Effects 0.000 claims abstract 2
- 239000003446 ligand Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 229960001844 tubocurarine Drugs 0.000 claims description 6
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 230000006472 autoimmune response Effects 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 4
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 229950000405 decamethonium Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 101710138657 Neurotoxin Proteins 0.000 claims 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 claims 1
- MTCUAOILFDZKCO-UHFFFAOYSA-N Decamethonium Chemical compound C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C MTCUAOILFDZKCO-UHFFFAOYSA-N 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 241000251733 Tetronarce californica Species 0.000 abstract description 3
- 108010041397 CD4 Antigens Proteins 0.000 abstract description 2
- 230000001851 biosynthetic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 description 11
- 108020000715 acetylcholine receptors Proteins 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 230000001713 cholinergic effect Effects 0.000 description 8
- 230000003278 mimic effect Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 230000024033 toxin binding Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 239000000842 neuromuscular blocking agent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002642 cobra venom Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Polyamides (AREA)
- Developing Agents For Electrophotography (AREA)
- Paper (AREA)
- Battery Electrode And Active Subsutance (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL8368787A IL83687A (en) | 1987-08-30 | 1987-08-30 | Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions |
| DE3853910T DE3853910T2 (de) | 1987-08-30 | 1988-08-30 | Molekulare köder und deren verwendung. |
| AT88908569T ATE123224T1 (de) | 1987-08-30 | 1988-08-30 | Molekulare köder und deren verwendung. |
| EP88908569A EP0329778B1 (en) | 1987-08-30 | 1988-08-30 | Molecular decoyants and methods of use thereof |
| JP63507516A JP2791074B2 (ja) | 1987-08-30 | 1988-08-30 | 分子状デコイアント及びその使用方法 |
| AU23839/88A AU2383988A (en) | 1987-08-30 | 1988-08-30 | Molecular decoyants and methods of use thereof |
| US07/410,778 US5770572A (en) | 1987-08-30 | 1988-08-30 | Methods and compositions using molecular decoyants for ameliorating the undesired effects of foreign agents which bind to endogenous receptors |
| CA000576111A CA1336489C (en) | 1987-08-30 | 1988-08-30 | Molecular decoyants and methods of use thereof |
| PCT/US1988/002991 WO1989001779A1 (en) | 1987-08-30 | 1988-08-30 | Molecular decoyants and methods of use thereof |
| FI892005A FI100169B (fi) | 1987-08-30 | 1989-04-27 | Menetelmä molekulaarisen syötin valmistamiseksi |
| NO89891787A NO891787L (no) | 1987-08-30 | 1989-04-28 | Molekylaere lokkemidler og fremgangsmaate for anvendelse derav. |
| DK198902119A DK175596B1 (da) | 1987-08-30 | 1989-05-01 | Molekylfælde og anvendelse deraf |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL8368787A IL83687A (en) | 1987-08-30 | 1987-08-30 | Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL83687A0 IL83687A0 (https=) | 1988-01-31 |
| IL83687A true IL83687A (en) | 1995-03-30 |
Family
ID=11058121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL8368787A IL83687A (en) | 1987-08-30 | 1987-08-30 | Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5770572A (https=) |
| EP (1) | EP0329778B1 (https=) |
| JP (1) | JP2791074B2 (https=) |
| AT (1) | ATE123224T1 (https=) |
| AU (1) | AU2383988A (https=) |
| CA (1) | CA1336489C (https=) |
| DE (1) | DE3853910T2 (https=) |
| DK (1) | DK175596B1 (https=) |
| FI (1) | FI100169B (https=) |
| IL (1) | IL83687A (https=) |
| NO (1) | NO891787L (https=) |
| WO (1) | WO1989001779A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02501192A (ja) * | 1987-09-04 | 1990-04-26 | バイオジェン インコーポレイテッド | 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法 |
| US5132402A (en) * | 1987-11-25 | 1992-07-21 | Agency Of Industrial Science And Technology | Adsorbent, method for production thereof, and method for use thereof |
| EP0318240A3 (en) * | 1987-11-25 | 1990-08-16 | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY MINISTRY OF INTERNATIONAL TRADE & INDUSTRY | Peptide, adsorbent, method for production thereof, and method for use thereof |
| US6919076B1 (en) * | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| US6908612B2 (en) | 1999-10-08 | 2005-06-21 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| ITRM20010563A1 (it) * | 2001-09-14 | 2003-03-14 | Univ Siena | Peptidi antigenici multipli come antidoti nell'intossicazione da veleno di serpente. |
| US8535672B2 (en) * | 2002-04-04 | 2013-09-17 | Yissum Research Development Of The Hebrew University Of Jerusalem | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof |
| RU2005102604A (ru) * | 2002-07-03 | 2005-09-10 | Перикор Сайенс, Инк. (Us) | Композиция гиалуроновой кислоты и способы применения |
| JP4495776B1 (ja) * | 2009-07-30 | 2010-07-07 | 日本製薬株式会社 | 融合蛋白質 |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| WO2015153647A1 (en) * | 2014-03-31 | 2015-10-08 | Mice With Horns, Llc | Method of preventing or reducing virus transmission in animals |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2570278B1 (fr) * | 1984-09-14 | 1987-02-13 | Pasteur Institut | Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise |
| US4761371A (en) * | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
| US5126433A (en) * | 1986-08-21 | 1992-06-30 | The Trustees Of Columbia University In The City Of New York | Soluble forms of the t cell surface protein cd4 |
| DE3751751T2 (de) * | 1986-08-21 | 1996-10-17 | Univ Columbia | Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids |
-
1987
- 1987-08-30 IL IL8368787A patent/IL83687A/en not_active IP Right Cessation
-
1988
- 1988-08-30 DE DE3853910T patent/DE3853910T2/de not_active Expired - Fee Related
- 1988-08-30 EP EP88908569A patent/EP0329778B1/en not_active Expired - Lifetime
- 1988-08-30 AU AU23839/88A patent/AU2383988A/en not_active Abandoned
- 1988-08-30 AT AT88908569T patent/ATE123224T1/de not_active IP Right Cessation
- 1988-08-30 US US07/410,778 patent/US5770572A/en not_active Expired - Lifetime
- 1988-08-30 WO PCT/US1988/002991 patent/WO1989001779A1/en not_active Ceased
- 1988-08-30 CA CA000576111A patent/CA1336489C/en not_active Expired - Fee Related
- 1988-08-30 JP JP63507516A patent/JP2791074B2/ja not_active Expired - Fee Related
-
1989
- 1989-04-27 FI FI892005A patent/FI100169B/fi not_active IP Right Cessation
- 1989-04-28 NO NO89891787A patent/NO891787L/no unknown
- 1989-05-01 DK DK198902119A patent/DK175596B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2791074B2 (ja) | 1998-08-27 |
| DK175596B1 (da) | 2004-12-13 |
| EP0329778B1 (en) | 1995-05-31 |
| IL83687A0 (https=) | 1988-01-31 |
| FI100169B (fi) | 1997-10-15 |
| US5770572A (en) | 1998-06-23 |
| WO1989001779A1 (en) | 1989-03-09 |
| EP0329778A1 (en) | 1989-08-30 |
| JPH02502538A (ja) | 1990-08-16 |
| FI892005A0 (fi) | 1989-04-27 |
| CA1336489C (en) | 1995-08-01 |
| DK211989D0 (da) | 1989-05-01 |
| NO891787L (no) | 1989-06-06 |
| DE3853910D1 (de) | 1995-07-06 |
| AU2383988A (en) | 1989-03-31 |
| EP0329778A4 (en) | 1990-12-27 |
| FI892005L (fi) | 1989-04-27 |
| DK211989A (da) | 1989-06-28 |
| ATE123224T1 (de) | 1995-06-15 |
| DE3853910T2 (de) | 1995-10-12 |
| NO891787D0 (no) | 1989-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL83687A (en) | Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions | |
| Koob et al. | Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats | |
| DE69332485T2 (de) | Immunmodulierende peptide | |
| Fainzilber et al. | Mollusc‐specific toxins from the venom of Conus textile neovicarius | |
| DE69527089T2 (de) | Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe | |
| DE3751553T2 (de) | Immunomodulare mittel und deren verwendung. | |
| Martin et al. | A metabolite of halothane covalently binds to an endoplasmic reticulum protein that is highly homologous to phosphatidylinositol-specific phospholipase C-α but has no activity | |
| JPH04503206A (ja) | ポリペプチドおよびこれをコードするｄｎａ | |
| DE69634438T2 (de) | Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits | |
| US6958323B2 (en) | Uses of α-conotoxin peptides | |
| CN110090296A (zh) | 一组与烟碱乙酰胆碱受体具有高度亲和力能快速起效的眼镜蛇神经毒素分子在镇痛上的应用 | |
| WO1987000179A1 (en) | Synthetic peptide-based anti-rabies compositions and methods | |
| US20140234401A1 (en) | Method of treating inflammation using human immunosuppressive protein | |
| Torrens et al. | Pharmacological characterisation of two tachykinin binding sites in the rat cerebral cortex | |
| Bahraoui et al. | Specificity and neutralizing capacity of antibodies elicited by a synthetic peptide of scorpion toxin. | |
| US5719264A (en) | Conotoxin peptides | |
| CN110772631A (zh) | 一组与烟碱乙酰胆碱受体具有高度亲和力能快速起效的眼镜蛇神经毒素分子在镇痛上的应用 | |
| DE69425745T2 (de) | Verfahren und zusammensetzungen zur behandlung der thrombose | |
| DE68928752T2 (de) | Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten | |
| JPS59501866A (ja) | 腸内ウイルスに対するワクチン接種に有用なポリペプチド | |
| WO1998051322A1 (en) | CONOPEPTIDES AuIA, AuIB AND AuIC | |
| NZ225167A (en) | Immunosuppresive peptides (minimum 9 residues) | |
| DE69726602T2 (de) | Hepatitis b inhibitoren | |
| JPH10506877A (ja) | ライグラス花粉アレルゲンのｔ細胞エピトープ | |
| Stabinsky | Studies on the phagocytosis stimulating peptide, tuftsin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |